Efficacy and Safety of Dalpiciclib in Hormone Receptor-positive Advanced Breast Cancer

NCT05578053 · clinicaltrials.gov ↗

RECRUITING

Status

420

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Dalpiciclib

Sponsor

Hebei Medical University Fourth Hospital